Objectives To evaluate the safety and efficacy of cisplatin（ DDP） and temozolomide （TMZ） in the treatment of recurrent high-grade gliomas with unmethylated MGMT promoter. Methods A total of 55 patients were included in this study. The patients were diagnosed with recurrent high-grade glioma with unmethylated MGMT promoter between 2016/04/30 and 2018/3/31. All patients in this group were confirmed by surgery and pathology as high-grade glioma（ WHO class Ⅲ or Ⅳ） and unmethylated MGMT promoter. During the follow-up period， the recurrence was confirmed with the pathological diagnosis of reoperation and/or the head MRI. Treatment of DDP and TMZ was performed. The adverse events rates and survival conditions were observed to evaluate the results. Results The efficiency for WHO Ⅲ glioma patients was 12.0%(3/25). The median survival time was 42 months. In the meanwhile， the efficiency for WHO Ⅳ glioma patients was 6.7%(2/30) and the median survival time was 17 months. The mean overall survival rate of 55 patients was 19 months. The adverse events in this group mainly included different degrees of myelosuppression， gastrointestinal symptoms and liver and kidney function damage， which were all recovered after targeted treatment. Conclusions DDP and TMZ play an effective role in the treatment of recurrent high-grade gliomas with unmethylated MGMT promoter.